Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 25,132 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 25,132 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $25.49, for a total value of $640,614.68. Following the completion of the sale, the insider now directly owns 10,777,092 shares in the company, valued at $274,708,075.08. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total transaction of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total value of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS traded up $0.28 during trading on Thursday, reaching $26.23. The stock had a trading volume of 354,639 shares, compared to its average volume of 377,444. The business’s 50-day moving average price is $21.72 and its 200 day moving average price is $19.09. NewAmsterdam Pharma has a 52 week low of $10.50 and a 52 week high of $27.29.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on NAMS shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Scotiabank raised their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $36.20.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma in the second quarter valued at approximately $38,000. Quarry LP grew its position in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares in the last quarter. Barclays PLC raised its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG acquired a new position in NewAmsterdam Pharma during the third quarter worth $128,000. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at about $187,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.